Sexually transmitted infection

Scientists Uncover Ways HIV is Sexually Transmitted in Women

Retrieved on: 
Wednesday, May 27, 2020
Medical specialties, Sexually transmitted diseases and infections, Retroviridae, Prevention of HIV/AIDS, Viruses, HIV, Lentiviruses, HIV/AIDS, Sexually transmitted infection

HIV is known to home in on a special type of immune cell called a CD4+ T cell.

Key Points: 
  • HIV is known to home in on a special type of immune cell called a CD4+ T cell.
  • "We still lack a fundamental understanding of the features of cells that first become infected upon HIV transmission in women," says Roan, who is also professor of urology at UC San Francisco.
  • "Our findings mayhelp explain the inconsistent effectiveness of oral PrEP or microbicides in protecting women from sexual transmission of HIV."
  • Scientists can now use these findings to develop strategies that could stem the ability of sexually transmitted HIV to infect women.

National Health Organizations Announce COVID-19 Contact Tracing Training

Retrieved on: 
Wednesday, April 29, 2020
Contact tracing, Public health, Sexually transmitted infection, Tracer

The course, " Making Contact: A Training for COVID-19 Contact Tracers ," will support ongoing public health agency efforts to prepare new contact tracers for their work of helping identify COVID-19 positive cases and those with whom they have been in close contact.

Key Points: 
  • The course, " Making Contact: A Training for COVID-19 Contact Tracers ," will support ongoing public health agency efforts to prepare new contact tracers for their work of helping identify COVID-19 positive cases and those with whom they have been in close contact.
  • "Our organizations recognize that contact tracing is critical to our nation's COVID-19 response.
  • The online training, which can be completed in about three hours, is designed to prepare individuals with little or no public health background to work as entry-level contact tracers.
  • "Contact tracing has been used for decades in our national response to STDs, HIV, and TB for one very good reason it works.

Venatorx Pharmaceuticals and GARDP Partner to Develop New Antibiotic for Hospital Acquired Infections With Limited Treatment Options

Retrieved on: 
Wednesday, April 29, 2020
Research, General Health, Pharmaceutical, Infectious diseases, Hospitals, Clinical trials, Science, Surgery, Nursing, FDA, Other Science, Health, Medical specialties, Health, Medicine, Infectious diseases, Healthcare-associated infections, Antimicrobial resistance, Evolutionary biology, Pharmaceuticals policy, Infection, Hospital-acquired infection, Sexually transmitted infection, Draft:Global Antibiotic Research and Development Partnership, Cefepime-Taniborbactam, Venatorx Pharmaceuticals, GARDP

In Europe, hospital infections are responsible for 37,000 attributable deaths annually , whereas in the United States, 98,000 deaths are attributed to hospital infections annually .

Key Points: 
  • In Europe, hospital infections are responsible for 37,000 attributable deaths annually , whereas in the United States, 98,000 deaths are attributed to hospital infections annually .
  • While there are limited surveillance systems in low- and middle-income countries, indicators point to a higher burden of hospital infections .
  • Our collaboration with Venatorx enables us to accelerate the development of a critically needed treatment for antibiotic-resistant infections in adults and children.
  • We aim to develop five new treatments by 2025 to fight drug-resistant infections, focusing on sexually transmitted infections, sepsis in newborns and infections in hospitalized adults and children.

Evofem Biosciences to Report First Quarter 2020 Results and Provide Corporate Update on Wednesday, May 6, 2020

Retrieved on: 
Tuesday, April 28, 2020
Women's health, Sexual reproduction, Human reproduction, Articles, Gynaecology, Mycoplasma, RTT, Population, Reproductive health, Sexual intercourse, Vagina, Sexually transmitted infection

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health.

Key Points: 
  • Evofem Biosciences, Inc., (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health.
  • Evofem Biosciences aims to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections (STIs).
  • Phexxi and Multipurpose Vaginal pH Regulator (MVP-R) are trademarks of Evofem Biosciences, Inc.
  • Evofem Biosciences does not undertake any duty to update any forward-looking statement except as required by law.

The U.S. Sexual Wellness Market, Forecast to 2027 by Product (Sex Toys, Condoms, Personal Lubricants) and Distribution Channel (Retail Pharmacy, e-Commerce)

Retrieved on: 
Wednesday, April 8, 2020
RTT, Articles, Sexual reproduction, Human sexuality, Barrier contraception, Female condom, Vagina, Condom, Personal lubricant, Forecast period, Sexually transmitted infection, Sex toy

Sexual Wellness Market, Forecast to 2027 by Product (Sex Toys, Condoms, Personal Lubricants) and Distribution Channel (Retail Pharmacy, e-Commerce)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Sexual Wellness Market, Forecast to 2027 by Product (Sex Toys, Condoms, Personal Lubricants) and Distribution Channel (Retail Pharmacy, e-Commerce)" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. sexual wellness market size is expected to reach USD 13.2 billion by 2027, registering a CAGR of 8.3% over the forecast period.
  • Government is undertaking initiatives to create awareness and promote the use of contraceptives in the younger generation to control the rising prevalence of STDs.
  • Thus, the growing awareness about STDs among the youth is expected to drive the market over the forecast period.

U.S. Sexual Wellness Market Size, Share & Trends Analysis Report By Product, By Distribution Channel And Segment Forecasts, 2020 - 2027

Retrieved on: 
Wednesday, April 8, 2020
RTT, Barrier contraception, Female condom, Vagina, Statistical forecasting, Condom, Medical specialties, Fields of mathematics, Sexually transmitted infection, Personal lubricant, Forecast period, Forecasting

Sexual Wellness Market Size, Share & Trends Analysis Report By Product (Sex Toys, Condom, Personal Lubricants), By Distribution Channel (Retail Pharmacy, E-commerce), And Segment Forecasts, 2020 - 2027

Key Points: 
  • Sexual Wellness Market Size, Share & Trends Analysis Report By Product (Sex Toys, Condom, Personal Lubricants), By Distribution Channel (Retail Pharmacy, E-commerce), And Segment Forecasts, 2020 - 2027
    The U.S. sexual wellness market size is expected to reach USD 13.2 billion by 2027, registering a CAGR of 8.3% over the forecast period.
  • Thus, the growing awareness about STDs among the youth is expected to drive the market over the forecast period.
  • Further key findings from the study suggest:
    The fading stigma attached to sexual experimenting is a key factor boosting the market growth.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Evofem Biosciences to Present at Solebury Trout Virtual Investor Conference

Retrieved on: 
Friday, March 27, 2020
Sexual reproduction, Women's health, Human reproduction, Articles, RTT, Gynaecology, Mycoplasma, Midwifery, Reproductive health, Sexual intercourse, Vagina, Sexually transmitted infection

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health.

Key Points: 
  • Evofem Biosciences, Inc., (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health.
  • Evofem Biosciences aims to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections (STIs).
  • The Company's lead product candidate, Phexxi, is currently being reviewed by the U.S. Food and Drug Administration for prevention of pregnancy.
  • Phexxi and Multipurpose Vaginal pH Regulator (MVP-R) are trademarks of Evofem Biosciences, Inc.

Long Beach: AHF Expands Wellness Center Services Offering Free STD/HIV Screening & Treatment

Retrieved on: 
Monday, March 9, 2020
AIDS, Public policy, Government, State, Local, Health, Infectious diseases, General Health, Pharmaceutical, RTT, Sexually transmitted diseases and infections, Infectious causes of cancer, Medical specialties, Health, Medicine, AIDS Healthcare Foundation, Sexually transmitted infection, AHF, Gonorrhea, Chlamydia, National Centre for HIV/AIDS Dermatology and STDs, Cambodia

The AHF Long Beach Wellness Center, 3500 E. Pacific Coast Highway, Long Beach CA.

Key Points: 
  • The AHF Long Beach Wellness Center, 3500 E. Pacific Coast Highway, Long Beach CA.
  • 90804, in collaboration with the Los Angeles County Public Health Department offers free HIV and STD testing and treatment and is operated by AIDS Healthcare Foundation (AHF) .
  • AHF Wellness Centers provide access to the community for confidential and free testing for HIV and STDs including Chlamydia, Gonorrhea, and Syphilis.
  • The clinic also offers free treatment for STDs as well as, Linkage to HIV Primary Care and Partner Notification Services.

Evofem Biosciences to Report Fourth Quarter and Year-end 2019 Results and Provide Corporate Update on March 12, 2020

Retrieved on: 
Tuesday, March 3, 2020
Behavior, Sexual reproduction, RTT, Human sexuality, Fertility, Sexual acts, Mycoplasma, Sexually transmitted infection, Sexual intercourse

If participating by phone, please dial in approximately 10 minutes prior to the start of the call.

Key Points: 
  • If participating by phone, please dial in approximately 10 minutes prior to the start of the call.
  • A telephone replay will be available approximately two hours after the call throughTuesday, March 17, 2020 at(855) 859-2056 (U.S.) or(404) 537-3406 (International), access code 5595046.
  • Evofem Biosciences aims to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections (STIs).
  • Amphorais a registered trademark and MVP-R is a trademark of Evofem Biosciences, Inc.

Evofem Biosciences Appoints Former FDA Division Director Lisa Rarick, M.D., to its Board of Directors

Retrieved on: 
Wednesday, February 26, 2020
RTT, Mycoplasma, Sexually transmitted infection

SAN DIEGO, Feb. 26, 2020 /PRNewswire/ --Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced the appointment of Lisa Rarick, M.D., F.A.C.O.G., to its Board of Directors.

Key Points: 
  • SAN DIEGO, Feb. 26, 2020 /PRNewswire/ --Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced the appointment of Lisa Rarick, M.D., F.A.C.O.G., to its Board of Directors.
  • "Her medical training, regulatory expertise and personal passions all align perfectly with the Company's mission, and we are thrilled to welcome her to the Board."
  • Evofem Biosciences aims to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections (STIs).
  • These forward-looking statements should not be relied upon as representing Evofem's views as of any date subsequent to the date hereof.